End-to-end CDMO Metrics, Inc. offers a complete concept to commercialization solution under one FDA site registration, presenting a compelling value proposition to clients seeking streamlined development, analytical testing, and pilot to commercial manufacturing without multiple transfers.

Near-term Growth Recent facility expansion to Greenville, NC, combined with a high client re-engagement rate (over 95% of clients would work with Metrics again) signals strong service demand and potential for additional capacity-driven contracts in formulation development and commercial manufacturing.

Strategic Acquisition The 2022 acquisition by Catalent indicates strategic validation and potential access to larger customer networks and distribution channels, creating opportunities to upsell integrated services to Catalent’s client base while maintaining Metrics’ end-to-end capabilities.

OSD Niche Advantage Specialization in novel oral dosage forms and end-to-end CDMO services positions Metrics to win projects from small-to-mid biotech and specialty pharma firms aiming for rapid concept-to-market timelines and scale-up without site transfers.

Marketing & People Key leadership addition in business development and a growing, multi-client portfolio offer potential for targeted outreach to early-stage and mid-stage pharma companies; focus on case studies and scalable examples of successful scale-up could drive new contract opportunities.